drugset
Drugs / Onalespib
last change Oct 2022 re-read 2 minutes ago

Onalespib

also known as AT13387 · A13387 · AT-13387 LACTATE · ATI-13387A · ATI-13387AU · ATI-13387X · CPD 35 · ONALESPIB (AT13387) · +2 more

Small molecule

Developed for
metastatic malignant neoplasm · triple-negative breast carcinoma · non-small cell lung carcinoma · ovarian serous adenocarcinoma · primary peritoneal serous adenocarcinoma · anaplastic large cell lymphoma · breast cancer · diffuse large B-cell lymphoma
+13 more · fallopian tube carcinoma · fallopian tube serous adenocarcinoma · gastrointestinal stromal tumor · high grade malignant neoplasm · hypopharynx squamous cell carcinoma · invasive breast carcinoma · laryngeal squamous cell carcinoma · mantle cell lymphoma · metastatic melanoma · metastatic neoplasm · oral cavity squamous cell carcinoma · oropharynx squamous cell carcinoma · prostate cancer
Investigated by
National Cancer Institute (NCI) · Astex Pharmaceuticals, Inc.

Trials 13 · a red edge is where a trial was stopped

today NCT02898207 · Ph 1 NCT02503709 · Ph 1 NCT02535338 · Ph 1/2 NCT02572453 · Ph 2 NCT02627430 · Ph 1 NCT02474173 · Ph 1 NCT02381535 · Ph 1 NCT02097225 · Ph 1 NCT01712217 · Ph 1/2 NCT01685268 · Ph 1/2 NCT01294202 · Ph 2 NCT01246102 · Ph 1 NCT00878423 · Ph 1
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 18 trials
Phase 1 NCT02898207 May 2017 → Jul 2020 fallopian tube serous adenocarcinoma, high grade malignant neoplasm, metastatic malignant neoplasm, ovarian serous adenocarcinoma +2 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT02503709 Sep 2016 → Aug 2020 metastatic malignant neoplasm National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT02627430 Mar 2016 → Mar 2019 fallopian tube carcinoma, ovarian serous adenocarcinoma, primary peritoneal serous adenocarcinoma, triple-negative breast carcinoma National Cancer Institute (NCI) Withdrawn No outcome recorded
Phase 1 NCT02474173 Jan 2016 → Oct 2022 invasive breast carcinoma, triple-negative breast carcinoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1 NCT02381535 Oct 2015 → Apr 2020 hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT02097225 May 2014 → Mar 2019 cutaneous melanoma, metastatic malignant neoplasm, metastatic melanoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1 NCT01246102 Nov 2010 → Dec 2013 breast cancer National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00878423 May 2008 → May 2013 metastatic neoplasm Astex Pharmaceuticals, Inc. Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT02535338 Apr 2016 → Sep 2021 non-small cell lung carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT01712217 Oct 2012 → Dec 2016 non-small cell lung carcinoma Astex Pharmaceuticals, Inc. Completed No outcome recorded
Phase 1/2 NCT01685268 Sep 2012 → Jul 2014 prostate cancer Astex Pharmaceuticals, Inc. Completed No outcome recorded
Phase 22 trials
Phase 2 NCT02572453 Apr 2016 → Mar 2021 anaplastic large cell lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 2 NCT01294202 Mar 2011 → Apr 2013 gastrointestinal stromal tumor Astex Pharmaceuticals, Inc. Completed No outcome recorded

Evidence & citations 14 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as Onalespib “Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387)” PMID 26082332 ↗ Jun 2015
8

“Onalespib (AT13387) is a potent non-ansamycin HSP90 inhibitor.” PMID 27156227 ↗ May 2016

NCT02898207 ↗

NCT02503709 ↗

NCT02381535 ↗

NCT02535338 ↗

NCT02474173 ↗

NCT02097225 ↗

NCT02572453 ↗
Known as A13387 ChEMBL registry synonym — accepted as the source's own label CHEMBL1214827 ↗
Known as AT-13387 LACTATE ChEMBL registry synonym — accepted as the source's own label CHEMBL1214827 ↗
Known as AT13387 “Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387)” PMID 26082332 ↗ Jun 2015
5

“Onalespib (AT13387) is a potent non-ansamycin HSP90 inhibitor.” PMID 27156227 ↗ May 2016

NCT00878423 ↗

NCT01685268 ↗

NCT02627430 ↗

NCT01712217 ↗
Known as ATI-13387A ChEMBL registry synonym — accepted as the source's own label CHEMBL1214827 ↗
Known as ATI-13387AU ChEMBL registry synonym — accepted as the source's own label CHEMBL1214827 ↗
Known as ATI-13387X ChEMBL registry synonym — accepted as the source's own label CHEMBL1214827 ↗
Known as CPD 35 ChEMBL registry synonym — accepted as the source's own label CHEMBL1214827 ↗
Known as ONALESPIB (AT13387) ChEMBL registry synonym — accepted as the source's own label CHEMBL1214827 ↗
Known as Onalespib l-lactate ChEMBL registry synonym — accepted as the source's own label CHEMBL1214827 ↗
Known as Onalespib Lactate “Drug: Onalespib Lactate” NCT02535338 ↗
Action Inhibit “Onalespib (AT13387) is a potent non-ansamycin HSP90 inhibitor.” PMID 27156227 ↗ May 2016
Modality Small molecule — CHEMBL1214827 ↗
Route Intravenous “one hour intravenous (IV) infusions” NCT00878423 ↗